Literature DB >> 11027455

Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C.

C O Tacket1, J Galen, M B Sztein, G Losonsky, T L Wyant, J Nataro, S S Wasserman, R Edelman, S Chatfield, G Dougan, M M Levine.   

Abstract

Attenuated Salmonella enterica serovar Typhi vaccine strain CVD 908-htrA was used as a vector to deliver fragment C of tetanus toxin as a single-dose oral tetanus vaccine candidate to elicit protective levels of serum tetanus antitoxin. Twenty-one healthy adult volunteers received doses of 1.6 x 10(7) to 8.2 x 10(9) CFU of one of two strains, CVD 908-htrA(pTETnir15) or CVD 908-htrA(pTETlpp), which contained plasmid-encoded fragment C, with sodium bicarbonate, and the safety and immune responses to serovar Typhi antigens and tetanus toxin were assessed. No volunteer had fever or positive blood cultures after vaccination, although diarrhea occurred in 3 volunteers and vomiting in 2 volunteers within 3 weeks after vaccination. Most volunteers excreted the vaccine strain in the first 72 h after vaccination. Three of nine volunteers who received 10(8) CFU or higher doses of the CVD 908-htrA(pTETlpp) construct developed rises in serum antitoxin antibodies. The serum and cellular immune responses to serovar Typhi antigens were less frequent than those previously observed in volunteers who ingested the parent strain CVD 908-htrA. This study demonstrates that fragment C of tetanus toxin delivered orally to volunteers in an S. Typhi vector can elicit protective levels of serum antitoxin. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027455     DOI: 10.1006/clim.2000.4924

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  27 in total

Review 1.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

Review 2.  Bacterial infectious disease control by vaccine development.

Authors:  Roy Curtiss
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 3.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 4.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

5.  Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909.

Authors:  Rezwanul Wahid; Rosangela Salerno-Gonçalves; Carol O Tacket; Myron M Levine; Marcelo B Sztein
Journal:  Vaccine       Date:  2006-11-03       Impact factor: 3.641

6.  Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development.

Authors:  Li-Mei Chen; Gabriel Briones; Ruben O Donis; Jorge E Galán
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

7.  Cross-reactive multifunctional CD4+ T cell responses against Salmonella enterica serovars Typhi, Paratyphi A and Paratyphi B in humans following immunization with live oral typhoid vaccine Ty21a.

Authors:  Rezwanul Wahid; Stephanie Fresnay; Myron M Levine; Marcelo B Sztein
Journal:  Clin Immunol       Date:  2016-09-12       Impact factor: 3.969

8.  Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid vaccine in humans.

Authors:  R Wahid; R Salerno-Gonçalves; C O Tacket; M M Levine; M B Sztein
Journal:  Mucosal Immunol       Date:  2008-07-02       Impact factor: 7.313

9.  Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers.

Authors:  Alejandra V E Capozzo; Lilian Cuberos; Myron M Levine; Marcela F Pasetti
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains.

Authors:  O G Gómez-Duarte; M F Pasetti; A Santiago; M B Sztein; S L Hoffman; M M Levine
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.